Methods: We present a photographic case series of 8 paediatric patients with PD exit site infections and/or over-granulation successfully treated with topical medical grade honey in place of topical antibiotic mupirocin, accompanied

by a literature review of medical honey for the treatment of paediatric wounds. Results: Improvement was observed in all cases, assessed by modified Twardowski criteria, from a median score of 3 (‘acute infection’) to a median score of 1 (‘good’). Conclusions: Medical grade honey is the first line prophylactic exit-site ointment in peritoneal dialysis exit-sites at our institution. We are increasingly turning to honey to salvage infected exit sites threatening the need for removal, with Ibrutinib much success. Increasing case reports are suggesting improvement in infected and poorly healing wounds in children with complex medical conditions. 253 PROTEINURIA IN DECEASED KIDNEY DONORS. DOES IT INFLUENCE RECIPIENT OUTCOME? T YING1, K POLKINGHORNE1,2,

W MULLEY2, H OPDAM3, J KANELLIS1,2 Y-27632 nmr 1Department of Nephrology, Monash Health, Clayton, Victoria; 2Monash University Department of Medicine, Clayton, Victoria; 3Donatelife Victoria, Carlton, Australia Aim: To determine whether the detection of proteinuria in deceased donors influences recipient outcomes. Background: Proteinuria is common in patients with critical illness. The effect of pre-donation proteinuria in deceased donors on recipient outcomes is unknown. DonateLife Victoria began collecting proteinuria data on most donors after 04/2011. This was driven by a demand for this information from transplanting

units due to an increase in marginal donors being offered. Methods: Victorian deceased kidney donors accepted by our institution from 04/2011–12/2012 and associated recipient outcomes were reviewed. Proteinuria was defined as urine protein/creatinine ratio (UPCR) ≥45 mg/mmol based on UK CKD guidelines. DonateLife recorded UPCR in 66/72 cases. We assessed whether donor proteinuria was associated with donor factors (age, diabetes, hypertension, cardiovascular disease) or recipient Cyclic nucleotide phosphodiesterase outcomes including 12mth graft function. Results: Two donors and recipients were excluded from analysis because of early graft loss. 26/64 (40.6%) donors had proteinuria. Proteinuria was not associated with donor age, hypertension, diabetes, cardiovascular or cerebrovascular disease, cardiac or brain death, or delayed graft function requiring dialysis. Proteinuria was associated with reduced early graft function (day 7 recipient eGFR with donor proteinuria vs no proteinuria: 23 ± 19 vs 36 ± 24 mL/min; P = 0.03). There was no association with function at later time points (12mth recipient eGFR with donor proteinuria vs no proteinuria: 50 ± 16 vs 57 ± 21 mL/min; P = 0.16).